Stocks
Mutual Funds
ETFs
Pro Tools
Terminal
WealthView
Pricing
Learn More
stocks
JAGSNPHARM
JAGSNPHARM

Jagsonpal Pharmaceuticals Ltd.

NSE: JAGSNPHARM
BSE: 507789
Sector: Healthcare
Industry: Pharmaceuticals
242.50-1.5 (-0.61%)
26 Aug, 12:00 AM

Stock Scores

Quality Score

93.8 / 100

Value Score

38.1 / 100

Price Momentum Score

77.1 / 100

QVM Score

88.5 / 100

Key Metrics

Market Cap
1599.46
P/E (TTM)
35.17
P/B
5.79
P/S (TTM)
5.44
EV/EBITDA
24.57
CAPE (5Y)
47.55
ROE (TTM)
16.69
ROCE (TTM)
18.23
ROA (TTM)
14.48
Avg 3Y ROE
18.53
Earnings 3Y CAGR
12.03
Sales 3Y CAGR
7.54
Sales 5Y CAGR
6.32
Debt/Equity
0.03
Consensus TP
-
Strong Buy %
-
Promoter Holding
69.05
Pledged %
0.00

Share Price

Track Jagsonpal Pharmaceuticals Ltd.'s current share price, historical price chart, 52-week high/low, and performance across different time periods.

242.50-1.5 (-0.61%)
3.81% in past 1 year
1 Week returns: 5.41 %
Low
229.5
High
248.0
1 Month returns: 8.50 %
Low
217.2
High
263.7
1 Year returns: 3.81 %
Low
154.9
High
264.6
3 Year CAGR: 12.23 %
Low
109.4
High
328.0
5 Year CAGR: 31.37 %
Low
49.2
High
328.0
Note: Prices may be delayed by a few minutes. For historical calculations, prices are adjusted for splits, bonus and rights issue. Percentage change shown is absolute irrespective of the period.

Stock Analysis

Fundamental analysis overview of Jagsonpal Pharmaceuticals Ltd. covering key investment insights, growth drivers, risk factors, and potential red flags.

Views
Red Flags
Positive
Strong price momentum

Price Momentum score of 77.1 indicates that the stock has strong price momentum. Research has shown that stocks with higher momentum continue to outperform in the near term

What is Price Momentum score?

77.1 / 100

High and improving operating margin

The company reported strong operating margin of 17.65% for 12-month ended 30 Jun 2026 and operating margin improved by 151 bps from 1 year ago

What is Operating profit margin?

Low Debt to Equity, not much change from last year

The company has low Debt to Equity of 0.03 as on 30 Jun 2026 and Debt to Equity decreased marginally by 0.01 in the last 1 year

What is Debt to Equity?

Consistently pays dividend

The company has not missed dividend payments once in the last 3 financial years

What is Dividend streak?

Company is net cash

The company is net cash i.e., cash and cash equivalents exceed total debt indicating a healthy balance sheet

What is Net Debt ?

Negative
Expensive and at a premium to industry median P/E

PE TTM of 35.17 indicates that the stock is expensive on a standalone basis and is at a 15.12% premium to industry median P/E

What is P/E Ratio?

Median: 30.55
Value 35.17
-0.99726.77
Low revenue growth and lower than median growth of industry

The company delivered moderate revenue growth of 3.87% for 12-month ended 30 Jun 2026 and the growth was 6.72 percentage points lower than median growth of industry

What is Sales growth (1Y)?

Median: 10.59
Value 3.87
-99.6111701.8
Low EPS growth and lower than median growth of industry

The company delivered moderate EPS growth of -25.37% for 12-month ended 30 Jun 2026 and the growth was 32.57 percentage points lower than median growth of industry

What is EPS growth (1Y)?

Neutral
High ROE but declining trend

The company reported strong ROE of 16.69% for 12-month ended 30 Jun 2026 but ROE declined by -922 bps from 1 year ago

What is ROE (FY)?

Company's earnings are of moderate quality

Earnings quality score of 64.8 indicates that the company's earnings are of moderate quality. Earnings quality is measured using combination of earnings persistence, probability of manipulation and earnings to cash conversion

What is Earnings quality score?

64.8 / 100

Moderate dividend yield

The company has a moderate dividend yield of 1.65%

What is Dividend yield?

No red flags found!
No significant red flags found in the stock.

Financial Snapshot

See detailed analysis

Multi-year trends for Jagsonpal Pharmaceuticals Ltd. covering revenue, net profit, ROE, and EBITDA for a quick view of financial health over time.

Net Revenue FY
00k0k0k236.7 CrMar 2023208.7 CrMar 2024268.7 CrMar 2025287.2 CrMar 2026
Profit After Tax FY
00k0k0k26.7 CrMar 202322.5 CrMar 202455.4 CrMar 202543.1 CrMar 2026
ROE FY
0%10%20%30%18.4%Mar 202313.0%Mar 202425.9%Mar 202516.7%Mar 2026
EBITDA FY
00k0k0k34.8 CrMar 202323.1 CrMar 202451.1 CrMar 202558.1 CrMar 2026

Jagsonpal Pharmaceuticals Ltd. Shareholding Pattern

Quarterly breakdown of Jagsonpal Pharmaceuticals Ltd. ownership including promoter, FII, DII, mutual fund, and public holdings as disclosed to NSE/BSE.

Mar 2020Jun 2020Sep 2020Dec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Total Promoter
70.34
70.34
70.34
70.34
70.34
70.34
70.34
70.34
68.71
68.71
68.72
68.71
68.71
68.71
68.71
68.48
68.09
68.04
67.97
67.81
67.78
67.65
67.54
67.39
67.89
69.05
Indian Promoter
70.34
70.34
70.34
70.34
70.34
70.34
70.34
70.34
68.71
68.71
68.72
68.71
24.99
24.99
24.99
24.90
24.76
24.74
24.72
24.66
24.65
24.60
24.56
24.51
25.12
25.55
Foreign Promoter
-
-
-
-
-
-
-
-
-
-
-
-
43.73
43.73
43.73
43.58
43.33
43.30
43.25
43.15
43.13
43.05
42.98
42.88
42.77
43.50
Institutions
0.01
0.00
0.00
0.00
0.00
0.00
0.12
0.20
0.67
0.68
0.41
0.88
0.93
1.20
1.21
1.35
1.58
1.95
2.41
2.10
2.10
2.23
2.21
2.27
2.66
2.92
Mutual Funds / UTI
-
-
-
-
-
-
-
-
-
-
0.00
-
-
-
-
-
-
-
0.11
-
-
-
-
-
-
-
FI/Bank/Insurance
0.01
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Govt
-
-
-
-
0.00
0.00
0.00
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
FII
0.00
0.00
0.00
0.00
0.00
0.00
0.11
0.20
0.00
0.00
0.13
0.00
0.00
0.37
0.38
0.53
0.73
1.10
2.30
2.10
2.10
2.17
2.12
2.12
2.44
2.30
Other Institutions
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.20
0.66
0.67
0.28
0.88
0.92
0.82
0.82
0.82
0.84
0.85
0.00
0.00
0.00
0.05
0.08
0.15
0.22
0.62
Non-Institution
29.66
29.66
29.66
29.66
29.65
29.65
29.54
29.46
30.61
30.61
30.85
30.41
30.36
30.08
30.08
30.17
30.33
30.01
29.62
30.08
30.11
30.12
30.25
30.34
29.45
28.03
Bodies Corporate
1.69
1.67
1.80
0.85
1.12
0.77
3.57
3.07
5.82
3.85
2.49
3.94
2.84
2.91
2.65
2.78
3.54
3.44
2.99
2.98
2.63
2.54
2.49
2.49
2.51
2.61
Others (incl. Retail)
No. of shareholders
27.97
8,978
27.99
9,574
27.86
10,265
28.81
12,018
28.53
12,479
28.88
14,537
25.97
14,261
26.39
19,932
24.79
17,014
26.76
16,092
28.36
14,848
26.47
14,435
27.52
13,986
27.17
13,675
27.43
15,945
27.39
15,687
26.79
16,181
26.57
15,638
26.63
15,514
27.10
18,328
27.48
20,953
27.58
22,765
27.76
24,512
27.85
24,763
26.94
26,120
25.42
24,040

Holdings and Presence

Indices and prominent investors with a stake in this stock.

Index Presence

Jagsonpal Pharmaceuticals Ltd. is not part of any tracked index.

Bulk, Block and Insider Trades

Recent bulk deals, block deals, and insider trading activity in Jagsonpal Pharmaceuticals Ltd. shares as reported to NSE and BSE.

NameMonthTransactionHolding % pre transactionAverage priceQty.Transaction value
Rajpal Singh Kochhar for and on behalf of Aresko Progressive Private Limited acting in capacity as a trustee of the Aresko Progressive Trust; and as the representative partner of J&P Investments Partnership
Promoter Group
June-2022
Off Market (Disposal)
29th Jun 2022
64.10 %₹ 235.001.15 cr₹ 269.20 cr
Rajpal Singh Kochhar for and on behalf of Aresko Progressive Private Limited acting in capacity as a trustee of the Aresko Progressive Trust; and as the representative partner of J&P Investments Partnership
Promoter Group
February-2022
Market Sale (Disposal)
28th Feb 2022
64.94 %₹ 238.122.26 lac₹ 5.38 cr
Rajpal Singh Kochhar for and on behalf of Aresko Progressive Private Limited acting in capacity as a trustee of the Aresko Progressive Trust; and as the representative partner of J&P Investments Partnership
Promoter Group
February-2022
Market Sale (Disposal)
25th Feb 2022
65.71 %₹ 234.152.00 lac₹ 4.68 cr
INDERPAL SINGH KOCHHAR
Designated Person
January-2021
Market Purchase (Acquisition)
4th Jan 2021
0.21 %₹ 72.0617.64 k₹ 12.71 lac

Corporate Actions

History of Jagsonpal Pharmaceuticals Ltd. dividends, bonus issues, stock splits, rights issues, and other corporate events.

  1. Dividend₹ 2.50/share
    Record date: 4th Sep 2026Ex-date: 4th Sep 2026
    Announced on: 27th Apr 2026
  2. Dividend₹ 1.50/share
    Record date: 4th Sep 2026Ex-date: 4th Sep 2026
    Announced on: 17th Aug 2026
  3. Others
    Ex-date: 4th May 2026Announced on: 12th Mar 2026
    "On Market Tender Offer."
  4. Dividend₹ 2.50/share
    Record date: 12th Sep 2025Ex-date: 12th Sep 2025
    Announced on: 6th May 2025
  5. Stock Split1 : 3
    Ex-date: 8th Jan 2025Announced on: 23rd Oct 2024
    Nominal Value change from INR 05 INR 02.

Company Profile

Overview of Jagsonpal Pharmaceuticals Ltd. covering business description, industry classification, key management, financial ratios, and listed exchange details.

Jagsonpal Pharmaceuticals Limited is an India-based pharmaceutical company. The Company is primarily engaged in the manufacturing and trading of pharmaceutical products and active pharmaceutical ingredients (APIs). Its Gynaecology products include Divatrone, Endoreg, Cystelia-M, Fibristone, Yulipris...
Key personnel
Mr. Nirav Niranjankumar Vora
Chief Financial Officer
Mr. Amrut Medhekar
Chief Operating Officer
Mr. Pratham Rawal
Compliance Officer, Company Secretary
Mr. Rajpal Singh KochharD
Chairman Emeritus
Mr. Harsha RaghavanD
Non-Executive Chairman of the Board
Mr. Manish GuptaD
Managing Director, Director
Mr. Prithipal Singh KochharD
Non-Executive Director
Ms. Radhika Madhukar DudhatD
Non-Executive Independent Director
View all
Incorporated on
17 Aug 1978
Last Annual
31 Mar 2026
Last Interim
30 Jun 2026
No. of Employees
-
IPO date
13 Sep 1996
Free Float
1,57,92,478
Phone no.
+911126494519
Address
Plot No. 412-415, Nimai Tower, 3rd Floor, Phase-IV, Udyog Vihar Sec-18, GURGAON, 122015, India

Frequently Asked Questions

What is the current share price of Jagsonpal Pharmaceuticals Ltd.?
The current share price of Jagsonpal Pharmaceuticals Ltd. is ₹ 242.50 as of 26 Aug 2026.
What is the market capitalisation of Jagsonpal Pharmaceuticals Ltd.?
The market capitalisation of Jagsonpal Pharmaceuticals Ltd. stands at ₹ 1,599.46 Cr.
What is the PE ratio of Jagsonpal Pharmaceuticals Ltd.?
The Price-to-Earnings (PE) ratio of Jagsonpal Pharmaceuticals Ltd. is 35.17 as of the latest trailing twelve months data.
What is the ROE and ROCE of Jagsonpal Pharmaceuticals Ltd.?
Jagsonpal Pharmaceuticals Ltd. has a Return on Equity (ROE) of 16.69% and a Return on Capital Employed (ROCE) of 18.23% as per the latest financial reports.
What is the 52-week high and low of Jagsonpal Pharmaceuticals Ltd.?
The 52-week high of Jagsonpal Pharmaceuticals Ltd. is - and the 52-week low is -.
What is the dividend yield of Jagsonpal Pharmaceuticals Ltd.?
The dividend yield of Jagsonpal Pharmaceuticals Ltd. is 1.65% based on the current market price.
What is the FII and DII holding in Jagsonpal Pharmaceuticals Ltd.?
Foreign Institutional Investors (FII) hold 2.30%, Domestic Institutional Investors (DII) hold 0.00% and retail/public investors hold 25.42% of Jagsonpal Pharmaceuticals Ltd. shares.
What sector does Jagsonpal Pharmaceuticals Ltd. belong to?
Jagsonpal Pharmaceuticals Ltd. operates in the Healthcare sector.
What is the beta of Jagsonpal Pharmaceuticals Ltd.?
The beta of Jagsonpal Pharmaceuticals Ltd. is 0.64, indicating its price volatility relative to the broader market. Over the past 1 year, Jagsonpal Pharmaceuticals Ltd. has delivered an absolute return of -2.41%.
What is the RSI of Jagsonpal Pharmaceuticals Ltd.?
The 14-day Relative Strength Index (RSI) of Jagsonpal Pharmaceuticals Ltd. is 59.83, placing it in the neutral zone. An RSI above 70 is considered overbought and below 30 is considered oversold.